Rare clots and heart issues by Covid vaccines call for larger trials in kids
Covaxin gets approval for 2-18 year olds; limited clinical trials may be inadequate to detect issues, say experts.
Covaxin gets approval for 2-18 year olds; limited clinical trials may be inadequate to detect issues, say experts.